Filtros de búsqueda

Lista de obras de Mark G Kris

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

artículo científico publicado en 2011

'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).

artículo científico publicado en 2004

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

artículo científico publicado en 2003

A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed

artículo científico publicado en 2011

A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life?

artículo científico publicado en 2005

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

artículo científico publicado en 2007

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy

artículo científico publicado en 2006

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors

artículo científico publicado en 2005

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

artículo científico publicado en 2010

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

artículo científico publicado en 2009

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

artículo científico publicado en 2006

A phase I trial of perillyl alcohol in patients with advanced solid tumors

artículo científico publicado en 2003

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

artículo científico publicado en 2006

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

artículo científico publicado en 2011

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer

artículo científico publicado en 2007

A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.

artículo científico publicado en 2002

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development

artículo científico publicado en 2010

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

artículo científico publicado en 2010

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

artículo científico publicado en 2014

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

artículo científico publicado en 2005

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

artículo científico publicado en 2010

Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial.

artículo científico publicado en 2013

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

artículo científico publicado en 2010

Analgesic effect of gefitinib in the treatment of non-small cell lung cancer

scientific article published on 01 March 2006

Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer

artículo científico publicado en 2009

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report

artículo científico publicado en 2010

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

artículo científico publicado en 2013

Antiemesis

scientific article published on 01 April 2012

Antiemetic guidelines: creating a more practical treatment approach

artículo científico publicado en 2002

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

artículo científico publicado en 2015

Antiemetics: American Society of Clinical Oncology clinical practice guideline update

artículo científico publicado en 2011

Antiemetics: american society of clinical oncology clinical practice guideline update.

artículo científico publicado en 2011

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

artículo científico publicado en 2013

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation

artículo científico publicado en 2014

Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine

artículo científico publicado en 2003

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

artículo científico publicado en 2004

Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline

artículo científico publicado en 2007

Characteristics of lung cancers harboring NRAS mutations

artículo científico publicado en 2013

Characterizing the cancer genome in lung adenocarcinoma

artículo científico publicado en 2007

Chemotherapy for early stage non-small cell lung cancer.

artículo científico publicado en 2001

Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.

artículo científico publicado en 2007

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology

artículo científico publicado en 2013

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

artículo científico publicado en 2014

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers

artículo científico publicado en 2014

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

artículo científico publicado en 2006

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

artículo científico publicado en 2009

Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma

article

Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion

artículo científico publicado en 2011

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial

artículo científico publicado en 2005

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

artículo científico publicado en 2014

Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.

artículo científico publicado en 2000

Comparison of CT volumetric measurement with RECIST response in patients with lung cancer

artículo científico publicado en 2016

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

artículo científico publicado en 2009

Comprehensive long-term care of patients with lung cancer: development of a novel thoracic survivorship program

artículo científico publicado en 2014

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

artículo científico publicado en 2004

Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases

artículo científico

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis

artículo científico publicado en 2010

Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas

artículo científico

DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors

artículo científico publicado en 2008

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

artículo científico publicado en 2014

Developing a cancer-specific geriatric assessment

artículo científico publicado en 2005

Development of inhalational agents for oncologic use.

artículo científico publicado en 2001

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas

artículo científico publicado en 2015

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

artículo científico publicado en 2011

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

artículo científico publicado en 2012

Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.

artículo científico publicado en 2000

Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update

artículo científico publicado en 2001

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials

artículo científico publicado en 2001

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

artículo científico publicado en 2004

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

artículo científico publicado en 2015

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

artículo científico publicado en 2011

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

artículo científico publicado en 2013

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

artículo científico publicado en 2008

EGFR mutations in small-cell lung cancers in patients who have never smoked.

artículo científico publicado en 2006

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

artículo científico publicado en 2012

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.

artículo científico publicado en 2010

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

scientific article published on 01 December 2000

Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway

artículo científico publicado en 2014

Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components

artículo científico publicado en 2008

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

artículo científico publicado en 2015

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

artículo científico publicado en 2005

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

artículo científico publicado en 2010

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer

artículo científico publicado en 2009

Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.

artículo científico publicado en 2002

Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer

artículo científico publicado en 2000

Foreword; challenging the 'one-size-fits-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer

artículo científico publicado en 2008

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

artículo científico publicado en 2008

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans

artículo científico publicado en 2011

Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.

artículo científico publicado en 2009

Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature

artículo científico publicado en 2003

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

artículo científico publicado en 2008

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

artículo científico publicado en 2010

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

artículo científico publicado en 2015

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

artículo científico publicado en 2012

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

artículo científico publicado en 2015

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

artículo científico publicado en 2013

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

artículo científico publicado en 2005

How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care

artículo científico publicado en 2005

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

artículo científico publicado en 2012

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

artículo científico publicado en 2005

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

artículo científico publicado en 2015

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

artículo científico publicado en 2011

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations

artículo científico publicado en 2011

Incorporation of crizotinib into the NCCN guidelines

artículo científico publicado en 2011

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach

artículo científico publicado en 2000

Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies

artículo científico publicado en 2010

Integration of Molecular Profiling into the Lung Cancer Clinic

artículo científico publicado en 2009

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

artículo científico publicado en 2005

Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy

artículo científico publicado en 2012

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

artículo científico publicado en 2013

Long-term results of combined-modality therapy in resectable non-small-cell lung cancer

artículo científico publicado en 2002

Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy

artículo científico publicado en 2007

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

artículo científico publicado en 2008

Lung cancer: computerized quantification of tumor response--initial results.

artículo científico publicado en 2006

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

artículo científico publicado en 2012

Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers

artículo científico publicado en 2013

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking

artículo científico publicado en 2014

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

artículo científico

Malignant pleural mesothelioma

article

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

artículo científico publicado en 2008

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

artículo científico publicado en 2011

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

artículo científico publicado en 2012

Molecular on/off switch.

artículo científico publicado en 2006

Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy

article

Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib

artículo científico publicado en 2009

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

artículo científico publicado en 2015

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4

artículo científico publicado en 2007

New approaches in the management of lung cancer.

artículo científico publicado en 2005

New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress

artículo científico publicado en 2002

Non-small cell lung cancer

artículo científico publicado en 2012

Non-small cell lung cancer clinical practice guidelines in oncology

scientific article published on 01 July 2006

Non-small cell lung cancer, version 1.2015.

artículo científico publicado en 2014

Non-small cell lung cancer, version 2.2013

article

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

artículo científico publicado en 2006

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

artículo científico publicado en 2011

Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer

artículo científico publicado en 2010

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

artículo científico publicado en 2014

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

artículo científico publicado en 2006

Pharmacokinetics and toxicity of weekly docetaxel in older patients

artículo científico publicado en 2006

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

artículo científico publicado en 2007

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

artículo científico publicado en 2000

Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.

artículo científico publicado en 2001

Phase I study of green tea extract in patients with advanced lung cancer

artículo científico publicado en 2004

Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs

artículo científico publicado en 2007

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

artículo científico publicado en 2000

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

artículo científico publicado en 2015

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

artículo científico publicado en 2011

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer

artículo científico publicado en 2008

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers

artículo científico publicado en 2013

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

scientific article published on 01 February 2000

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

artículo científico publicado en 2014

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

artículo científico publicado en 2012

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib

artículo científico publicado en 2011

Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2000

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

artículo científico publicado en 2010

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.

artículo científico publicado en 2013

Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.

artículo científico publicado en 2007

Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker

artículo científico publicado en 2012

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

artículo científico publicado en 2003

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

artículo científico publicado en 2014

Practical management of patients with non-small-cell lung cancer treated with gefitinib

artículo científico publicado en 2004

Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial

artículo científico publicado en 2011

Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

artículo científico publicado en 2004

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

artículo científico publicado en 2012

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

artículo científico publicado en 2005

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

artículo científico publicado en 2008

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

artículo científico publicado en 2015

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

artículo científico publicado en 2005

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

artículo científico publicado en 2007

Pulmonary Toxicity Associated With Erlotinib

article

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

artículo científico publicado en 2005

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

artículo científico publicado en 2008

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

artículo científico publicado en 2005

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

artículo científico publicado en 2011

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

artículo científico publicado en 2010

Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.

artículo científico publicado en 2012

Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma

artículo científico publicado en 2005

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab

artículo científico publicado en 2013

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

artículo científico publicado en 2015

SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma

artículo científico publicado en 2004

Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients

artículo científico publicado en 2009

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

artículo científico publicado en 2005

Serpins promote cancer cell survival and vascular co-option in brain metastasis

artículo científico publicado en 2014

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

artículo científico publicado en 2016

Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

artículo científico publicado en 2014

Small-cell lung cancers in patients who never smoked cigarettes.

artículo científico publicado en 2014

Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A.

artículo científico publicado en 2004

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

artículo científico publicado en 2005

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

artículo científico publicado en 2015

Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels

artículo científico publicado en 2007

Targeting lethal minimal residual disease in small cell lung cancer

artículo científico publicado en 2003

The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research

artículo científico publicado en 2012

The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease

scientific article published on 01 July 2002

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.

artículo científico publicado en 2003

The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement

artículo científico publicado en 2012

Thymic malignancies

artículo científico publicado en 2010

Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology

article

Trastuzumab in the treatment of non-small cell lung cancer.

artículo científico publicado en 2002

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

artículo científico publicado en 2014

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

artículo científico publicado en 2006

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

artículo científico publicado en 2014

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

artículo científico publicado en 2004

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin

artículo científico publicado en 2004

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes

artículo científico publicado en 2011

Variations in lung cancer risk among smokers.

artículo científico publicado en 2003

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis

artículo científico publicado en 2009

Why Do We Need Another Antiemetic? Just Ask

artículo científico publicado en 2003

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

artículo científico publicado en 2018

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

artículo científico publicado en 2002

Eficacia de gefitinib, un inhibidor del receptor tirosina quinasa del factor de crecimiento epidérmico, en pacientes sintomáticos con cáncer de pulmón de células no pequeñas: un ensayo aleatorizado.

artículo científico publicado en 2003

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda